Terns Pharmaceuticals (TERN) Conference Call Summary Company Overview - Terns Pharmaceuticals focuses exclusively on small molecules with validated mechanisms of action in areas of high unmet need, particularly in metabolic diseases and oncology [5][6][10]. Key Highlights from the Conference Call Phase I Study of TURN-601 - TURN-601 is a novel oral GLP-1 receptor agonist developed for obesity treatment, showing promising results in a Phase I study [4][10]. - The study demonstrated a statistically significant mean weight loss of up to 5.5% from baseline, or 4.9% when adjusted for placebo [10][11]. - 67% of subjects lost 5% or more body weight at the highest dose of 740 mg [11][20]. - TURN-601 was well tolerated, with no dose interruptions or discontinuations due to treatment-related adverse events [11][25]. Distinct Properties of TURN-601 - TURN-601 has a flat pharmacokinetic (PK) curve, allowing for once-daily dosing with sustained target coverage [9][30]. - The drug exhibits low solubility and high gut permeability, resulting in prolonged absorption and a favorable safety profile [30][32]. - The manufacturing process is scalable with low cost of goods, making it accessible for a large patient population suffering from obesity [9][10]. Future Development Plans - Terns Pharmaceuticals plans to initiate Phase II trials for TURN-601 in 2025, based on the positive Phase I results [9][10][37]. - The company is evaluating multiple options for the Phase II trial design to ensure an efficient path to approval [10][37]. Market Context and Competitive Landscape - The obesity market is evolving towards monotherapy and combination agents, with Terns having two oral metabolic assets in development that can enhance the effects of GLP-1 receptor agonists [37][38]. - TURN-501, another asset, has shown preclinical data indicating enhanced weight loss when combined with GLP-1s, targeting different metabolic pathways [38]. Additional Insights - The study's design included a randomized double-blind placebo-controlled approach, with a focus on both single and multiple ascending dose escalations [12][13]. - The majority of participants were male, which may influence weight loss outcomes, as literature suggests males generally lose less weight on GLP-1 agonists compared to females [17][99]. - The company is committed to engaging with regulatory agencies to optimize the Phase II study design and ensure a robust clinical program [37][92]. Conclusion - Terns Pharmaceuticals is positioned to advance TURN-601 into Phase II trials, leveraging its unique properties and favorable safety profile to address the significant unmet need in obesity treatment. The company is also exploring combination therapies to enhance treatment efficacy in diverse patient segments [39][40].

Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo adjusted) Well-tolerated with no treatment-related dose interruptions, reductions, or discontinuations even with rapid dose titration Distinct drug properties support potential to be a leading GLP-1R agonist Plans to initiate Phase 2 clinical trial in 2025 Company to host conference call today at 8:00 am ET FOSTER CITY, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TE ...

Shares of Terns Pharmaceuticals, Inc. (TERN) , a clinical-stage biopharmaceutical company, rose 29.6% in the past three months compared with the industry's growth of 7.4%. The stock outperformed the sector and the S&P 500 Index during the said time frame. The outperformance can be attributed to encouraging pipeline progress of its obesity and oncology candidates. TERN Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment Research Terns Targets Lucrative Obesity Market Terns is developing a p ...

Shares of Terns Pharmaceuticals, Inc. (TERN) have gained 3.7% over the past four weeks to close the last trading session at $7.95, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.21 indicates a potential upside of 78.7%. The average comprises seven short-term price targets ranging from a low of $5.50 to a high of $22, with a standard deviation of $5.92. While the lowest esti ...

Company Leadership Changes - Elona Kogan has been appointed as the chief legal officer of Terns Pharmaceuticals, bringing over 20 years of experience in the life sciences sector, including pivotal roles in IPOs and commercialization at Seer, Inc. and other pharmaceutical companies [1][6] - Mark Vignola, the current chief financial officer, will leave the company in a planned transition, continuing until a successor is found, expected to be by the end of January 2025 [2][3] Company Pipeline and Development - Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates targeting serious diseases such as oncology and obesity [3][6] - The company's pipeline includes three clinical-stage development programs: an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-β agonist, along with a preclinical GIPR modulator program [3]

FOSTER CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of smallmolecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Elona Kogan, Esq., as chief legal officer, effective immediately. Ms. Kogan brings a wealth of industry experience and has successfully guided several biotechnology companies through trans ...

"While GLP-1 receptor agonists facilitate weight loss by suppressing food intake, efficacy may be limited by metabolic adaptation, a counter regulatory process that lowers energy expenditure in response to weight loss. THR-β agonism, an orthogonal mechanism to GLP-1, appears to unlock additional efficacy of GLP-1 therapies by normalizing energy expenditure during weight loss, while preserving relative lean mass," said Emil Kuriakose, M.D., chief medical officer at Terns. "These exciting results suggest that ...

About TERN-501 FOSTER CITY, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of smallmolecule product candidates to address serious diseases, including oncology and obesity, today announced that preclinical data supporting TERN-501, a highly selective thyroid hormone receptor beta (THR-β) receptor agonist, in combination with a GLP-1 receptor agonist for obesity will be highlight ...

Terns carries a Zacks Rank #2 (Buy) at present. A couple of other top-ranked stocks in the biotech sector are Ligand Pharmaceuticals (LGND) and ALX Oncology Holdings (ALXO) , each carrying a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. In the past 30 days, the Zacks Consensus Estimate for Ligand's 2024 earnings per share (EPS) has increased 16 cents to $4.71. During the same time frame, the consensus estimate for 2025 EPS has increased 70 cents t ...

Shares of Terns Pharmaceuticals, Inc. (TERN) have gained 3.8% over the past four weeks to close the last trading session at $6.01, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.21 indicates a potential upside of 136.4%. The mean estimate comprises seven short-term price targets with a standard deviation of $5.92. While the lowest estimate of $5.50 indicates an 8.5% decline ...